Simcere Pharmaceutical Group Limited has circulated a proxy form outlining resolutions for its annual general meeting scheduled for 9:00 a.m. on 12 June 2026 at No. 800 Minbei Road, Minhang District, Shanghai, PRC. Key items to be tabled are as follows:

1. Financial Statements and Dividend • Shareholders will vote on the adoption of the audited consolidated financial statements for the year ended 31 December 2025. • The board proposes a final dividend of RMB0.18 per ordinary share, with directors authorised to execute all related actions for distribution.

2. Board Composition and Remuneration • Re-election of executive directors Mr. Tang Renhong and Mr. Wan Yushan, and independent non-executive director Mr. Song Ruilin. • Authorisation for the board to determine directors’ remuneration.

3. Auditor Re-appointment • KPMG is nominated for re-appointment as external auditor, with the board empowered to set the audit fee.

4. Share Capital Mandates • General mandate permitting the board to allot, issue and deal with shares up to 20% of the company’s issued share capital as at the meeting date. • Authority to repurchase shares on-market up to 10% of the issued share capital. • Conditional extension of the repurchase mandate to the issuance mandate, effectively increasing the potential issuance limit by the number of shares bought back.

5. Articles of Association • A special resolution seeks shareholder approval to adopt amended articles of association as described in Appendix III of the meeting circular dated 22 May 2026.

Proxy forms must be lodged with Computershare Hong Kong Investor Services Limited by 9:00 a.m. on 10 June 2026 for valid representation at the meeting.